Our primary hypothesis was that mice who received stroke that were then treated with recombinant human growth hormone (rhGH) for 28 days, starting at 48 h post-stroke, would improve performance in motor tasks relative to non-rhGH-treated stroke mice. Here, GH1 is linked to stroke disorder.